文献速递核素与放射性配体治疗肿瘤 PET/CT

剂量学分析显示[¹⁷⁷Lu]Lu-PSMA-617在非前列腺癌中清除快且吸收剂量低

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression.
PubMed 文献 · EJNMMI Res · 2026-02-24

本研究评估了[¹⁷⁷Lu]Lu-PSMA-617在5例既往[⁶⁸Ga]Ga-PSMA-11 PET/CT显示肿瘤病灶高摄取的晚期非前列腺癌患者中的剂量学,并与5例转移性去势抵抗性前列腺癌患者比较。结果显示非前列腺癌肿瘤病灶的平均有效半衰期和每注射活度的平均吸收剂量均显著低于前列腺癌组,而源器官剂量学无显著差异。结论认为对于诊断性PSMA高摄取的非前列腺恶性肿瘤,该治疗因肿瘤吸收剂量低而不太可能成为有效的抗肿瘤选择。

要点

  • 非前列腺癌肿瘤病灶平均有效半衰期显著短于前列腺癌(27.1±13.1 h vs. 74.9±23.1 h,p<0.001)。
  • 非前列腺癌肿瘤病灶每注射活度平均吸收剂量显著低于前列腺癌(0.49±0.40 Gy/GBq vs. 3.51±2.20 Gy/GBq,p<0.001)。
  • 两组间源器官吸收剂量或有效半衰期无显著差异。

核心结论

  • 在诊断性PSMA高摄取的非前列腺恶性肿瘤中,[¹⁷⁷Lu]Lu-PSMA-617因肿瘤有效半衰期短而导致肿瘤吸收剂量低,该治疗不太可能成为有效的抗肿瘤选择。

研究设计与样本

  • 评估5例非前列腺癌患者(乳腺癌、肾细胞癌、肝细胞癌和间变性星形细胞瘤)的剂量学数据,并与5例转移性去势抵抗性前列腺癌患者作为对照组比较。
  • 所有患者在[⁶⁸Ga]Ga-PSMA-11 PET/CT证实肿瘤病灶具有足够PSMA摄取后接受[¹⁷⁷Lu]Lu-PSMA-617治疗。
  • 治疗后剂量学通过系列全身扫描(注射后24、48和72–120小时)计算肿瘤和非肿瘤病灶的有效半衰期及吸收剂量,并比较非前列腺癌与前列腺癌患者。

主要发现

  • 非前列腺癌组肿瘤病灶平均有效半衰期为27.1±13.1 h,显著短于前列腺癌组的74.9±23.1 h(p<0.001)。
  • 非前列腺癌组肿瘤病灶每注射活度平均吸收剂量为0.49±0.40 Gy/GBq,显著低于前列腺癌组的3.51±2.20 Gy/GBq(p<0.001)。
  • 两组间源器官吸收剂量或有效半衰期无显著差异。

临床怎么用

  • 对于[⁶⁸Ga]Ga-PSMA-11 PET/CT显示肿瘤病灶高摄取的晚期非前列腺癌患者,不应仅凭诊断性高摄取选择[¹⁷⁷Lu]Lu-PSMA-617治疗,需考虑其肿瘤吸收剂量可能较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to evaluate the dosimetry for [177Lu]Lu-PSMA-617 in advanced non-prostate cancer (non-PCa) patients with previous intense radiotracer uptake of the tumor lesions on PET/CT using [68Ga]Ga-PSMA-11. RESULTS: Dosimetry data of 5 patients with non-prostate cancer (non-PCa group) were assessed and compared; Non-PCa tumors were breast cancer (BC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and anaplastic astrocytoma (AA). Five patients with metastatic castration-resistant prostate cancer (PCa group) were used as control-group. All patients were given [177Lu]Lu-PSMA-617 after proven sufficient PSMA uptake of tumor lesions by [68Ga]Ga-PSMA-11 PET/CT. Post-therapeutic dosimetry with serial whole-body scans (24, 48 and 72–120 h post-injection) included calculation of effective half-life and absorbed doses for tumor and non-tumor lesions and comparison between non-PCa and PCa patients. The mean effective half-life in tumor lesions was significantly shorter in non-PCa compared to PCa patients (27.1 ± 13.1 h vs. 74.9 ± 23.1 h, respectively, p < 0.001). Likewise, the mean absorbed dose per injected activity was significantly lower in tumor lesions of non-PCa compared to PCa (0.49 ± 0.40 Gy/GBq vs. 3.51 ± 2.20 Gy/GBq, respectively, p < 0.001). No significant differences for the source organ absorbed dose or effective half-life were observed between both groups. CONCLUSIONS: In non-prostate malignancy with impressive diagnostic PSMA-mediated tumor uptake, i.e. high tracer uptake at early time points in [68Ga]Ga-PSMA-11 PET/CT, [177Lu]Lu-PSMA-617 delivers a low tumor-absorbed dose due to a short effective half-life, therefore this therapy does not appear to be a potential antitumor option.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Khreish F, Rosar F, Burgard C, et al. Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression. EJNMMI Res. 2026. PMID: 41733872. doi:10.1186/s13550-026-01394-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。